These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 27514840)
21. BRCA to the future: towards best testing practice in the era of personalised healthcare. Capoluongo E Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S1-2. PubMed ID: 27514838 [No Abstract] [Full Text] [Related]
22. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272 [TBL] [Abstract][Full Text] [Related]
23. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K; MacMillan A; Meschino WS; Panabaker K; Perrier R; Provencher D; Schrader KA; Serfas K; Tomiak E; Wong N; Young SS; Gotlieb WH; Hoskins P; Kim RH; J Med Genet; 2018 Sep; 55(9):571-577. PubMed ID: 30042185 [TBL] [Abstract][Full Text] [Related]
24. New challenges for BRCA testing: a view from the diagnostic laboratory. Wallace AJ Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S10-8. PubMed ID: 27514839 [TBL] [Abstract][Full Text] [Related]
25. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018 [TBL] [Abstract][Full Text] [Related]
26. Genetic Testing After Previous BRCA Testing: A Case Study. Ward M Clin J Oncol Nurs; 2016 Dec; 20(6):660-663. PubMed ID: 27857264 [TBL] [Abstract][Full Text] [Related]
27. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Loman N; Bladström A; Johannsson O; Borg A; Olsson H Breast Cancer Res; 2003; 5(6):R175-86. PubMed ID: 14580253 [TBL] [Abstract][Full Text] [Related]
28. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? Mitchell R; Buckingham L; Cobleigh M; Rotmensch J; Burgess K; Usha L PLoS One; 2018; 13(4):e0195497. PubMed ID: 29659587 [TBL] [Abstract][Full Text] [Related]
29. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. Finch A; Wang M; Fine A; Atri L; Khalouei S; Pupavac M; Rosen B; Eisen A; Elser C; Charames G; Metcalfe K; Chang MC; Narod SA; Lerner-Ellis J Clin Genet; 2016 Mar; 89(3):304-11. PubMed ID: 26219728 [TBL] [Abstract][Full Text] [Related]
30. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Nicoletto MO; Donach M; De Nicolo A; Artioli G; Banna G; Monfardini S Cancer Treat Rev; 2001 Oct; 27(5):295-304. PubMed ID: 11871866 [TBL] [Abstract][Full Text] [Related]
31. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710 [TBL] [Abstract][Full Text] [Related]
32. Reproductive decision-making in young female carriers of a BRCA mutation. Donnelly LS; Watson M; Moynihan C; Bancroft E; Evans DG; Eeles R; Lavery S; Ormondroyd E Hum Reprod; 2013 Apr; 28(4):1006-12. PubMed ID: 23293217 [TBL] [Abstract][Full Text] [Related]
33. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541 [TBL] [Abstract][Full Text] [Related]
34. BRCA screening. Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543 [No Abstract] [Full Text] [Related]
35. The biological effects and clinical implications of BRCA mutations: where do we go from here? Stoppa-Lyonnet D Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841 [TBL] [Abstract][Full Text] [Related]
36. Psychological distress related to BRCA testing in ovarian cancer patients. Bjørnslett M; Dahl AA; Sørebø Ø; Dørum A Fam Cancer; 2015 Dec; 14(4):495-504. PubMed ID: 25980896 [TBL] [Abstract][Full Text] [Related]
37. Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms. Wu H; Wu X; Liang Z Gene Ther; 2017 Oct; 24(10):601-609. PubMed ID: 28771233 [TBL] [Abstract][Full Text] [Related]
38. Expanding the criteria for BRCA mutation testing in breast cancer survivors. Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129 [TBL] [Abstract][Full Text] [Related]
39. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families. Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278 [TBL] [Abstract][Full Text] [Related]
40. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]